HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adulterated OTCs Reach Dollar Tree, Third-Party Test Lab Missed Problems

Executive Summary

Warning links retailers to multiple manufacturers inspected after FDASIA in 2012 pointed FDA toward inspecting all ex-US firms supplying products available in US but that had yet to be inspected for compliance. Manufacturers also were placed on import alerts to prevent their products, including cosmetics as well as drugs, from reaching US.

You may also be interested in...



US FDA Warns Second Ningbo, China, OTC Firm In Two Weeks On Violations

Hand sanitizer, shampoo, acne scrub, other products available in US under brands including AuraFresh, Halsa, Spa Mystique deemed adulterated due to GMP problems found during an inspection at Pulisi Daily's facility in  city in Zhejiang Province.

Warnings Up As FDA Trims Its List Of Uninspected OTC Drug Manufacturers

Hundreds of foreign OTC drug firms marketing products in US had not been inspected for GMP compliance before FDA Safety and Innovation Act of 2012 pointed agency toward crossing those facilities off its list. Of the foreign OTC facilities inspected between June 2016 and January 2018, 25% received "official action indicated" inspection results, prompting warning letters and import alerts.

Manufacturing Compliance Updates In Brief: A Reduced Focus On Data Integrity

US FDA has issued at least 10 GMP warning letters in February and March to drug and API manufacturers in China, India, France, South Korea, Hong Kong, the Dominican Republic and the US. Common problems seen are failure to validate manufacturing processes, inadequate testing to conform that products meet specifications, and inadequate safeguards to prevent microbiological contamination, yet in a recent turn, only a few manufacturers had data integrity problems. FDA posts Form 483 reports issued to four manufacturers in India for GMP violations and adds six facilities to its drug GMP import alert.

Related Content

Topics

UsernamePublicRestriction

Register

RS149418

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel